Top Line

Modern announced On Wednesday it aims to report efficacy data of its COVID-19 vaccine in children aged 2-5 years by March, and hopes to evaluate its booster shot for children aged 12-17 as Covid-related hospitalizations for children have reached record levels.

important facts

- Advertisement -

If data from trials aged 2 to 5 is promising, the company says it will move forward with regulatory filings to gain approval from the U.S. Food and Drug Administration.

The FDA has not yet approved any COVID-19 vaccine for people aged 2 to 5, only pfizerThe vaccine is authorized for those ages 5 to 11.

Despite its initial two-dose vaccine not yet approved for people aged 12 to 17, Moderna said it is evaluating a booster dose for that age group.

Pfizer is also the only COVID-19 vaccine approved in the US for ages 12 to 17, although Moderna has received authorization in Europe, Australia and Canada.

FDA said Moderna told the agency in October that more time was needed to assess the company’s vaccine before approving it for the teen age group, possibly with an update coming later this month.

Moderna says it has begun evaluating lower doses for ages 6 to 11 and 12 to 17 to meet regulatory guidelines.

- Advertisement -